Overactivation of EGFR signaling in skeletal stem/progenitor cells promotes bone formation and repair

Yuxiang Hu, Yangyang Chen, Xiang Peng, Haitao Li, Guo‐Si‐Lang Zuo, Hao Xu, Fashuai Wu, Yi Wang, Zengwu Shao, Yulong WeiTheranostics 2025 · DOI

TL;DR

This study reveals that activating the Epidermal Growth Factor Receptor (EGFR) pathway specifically in skeletal stem/progenitor cells significantly accelerates bone fracture healing. By overexpressing an EGFR ligand (HBEGF) in these cells, researchers observed enhanced bone formation, improved repair, and increased angiogenesis, suggesting EGFR signaling as a promising therapeutic target for bone regeneration.

What Problem Does This Paper Address?

Bone fractures are a common and significant health issue, with a notable percentage failing to heal properly, leading to complications like nonunion, malunion, and chronic pain. While the general process of fracture healing is understood, the precise roles of specific signaling pathways and cell types within the complex cellular environment of bone repair remain areas of active investigation. Specifically, the function of EGFR signaling in skeletal stem and progenitor cells during bone healing was not well-defined, presenting a knowledge gap that this research aims to fill. Understanding these mechanisms is crucial for developing effective treatments for delayed healing and non-union fractures.

Methods

The researchers employed a multi-pronged approach:

  • Genetically Engineered Mouse Models: They created a novel mouse model (HBEGF Over<sup>Prx1</sup>) where the heparin-binding EGF-like growth factor (HBEGF), an EGFR ligand, was overexpressed specifically in Prx1-expressing cells, which are known skeletal stem/progenitor cells. This was achieved using a lineage tracing approach combined with a Cre-lox system and a diphtheria toxin receptor (DTR) model.
  • Fracture Models: Standardized midshaft femoral fracture models were used to study endochondral ossification, and critical-size calvarial defect models were used to investigate intramembranous ossification.
  • Micro-CT Analysis: High-resolution micro-computed tomography was extensively used to quantify bone structure, callus volume, bone mineral density, trabecular and cortical bone thickness, and overall fracture healing progress.
  • Histology and Immunohistochemistry: Staining techniques like H&E, Safranin O/Fast green, TRAP, OCN, and Endomucin were used to assess tissue morphology, bone formation, osteoclast activity, and vascularization.
  • Single-Cell RNA Sequencing (scRNA-seq): This powerful technique was used to analyze the cellular composition and gene expression profiles of fracture callus cells at the single-cell level, identifying key cell populations and their developmental trajectories.
  • In Vitro Assays: Isolated periosteal progenitor cells were used for Western blotting (to assess protein levels of EGFR signaling components), proliferation assays (CCK-8), apoptosis assays (Annexin V), colony-forming unit assays (CFU-F), migration assays (Transwell), and differentiation assays (ALP, Alizarin Red S for osteogenesis; Alcian Blue for chondrogenesis).
  • Pharmacological Inhibition: The EGFR inhibitor gefitinib and an ERK inhibitor (U0126) were used to block signaling pathways and assess their impact on fracture healing and cellular functions.

Datasets

Not explicitly discussed as datasets in the traditional machine learning sense. The study utilizes data generated from experiments on genetically modified mice and cell cultures.

Key Insights and Ideas

  • Prx1+ cells are key players: The study confirms that Prx1-expressing cells are a significant progenitor pool that gives rise to chondrocytes and osteoblasts, crucial for bone formation and repair.
  • HBEGF is highly expressed in fracture callus: During fracture healing, HBEGF expression dramatically increases within the callus, particularly in Prx1+ cells, suggesting its critical role in this process.
  • EGFR overactivation boosts bone mass: Even in non-injured mice, overactivating EGFR signaling in Prx1+ cells leads to increased trabecular and cortical bone mass, indicating a role in normal bone maintenance.
  • EGFR signaling promotes survival and migration: While not affecting proliferation, EGFR overactivation significantly protects periosteal progenitor cells from apoptosis and enhances their migration capabilities.
  • Indirect angiogenesis promotion: HBEGF overexpression in periosteal progenitors indirectly promotes angiogenesis by increasing VEGFA expression, which is vital for delivering nutrients and growth factors to the healing site.
  • EGFR is essential for both endochondral and intramembranous ossification: The study demonstrates that EGFR activation by HBEGF promotes bone regeneration in both fracture healing (endochondral) and calvarial defects (intramembranous).

Key Results

  • Accelerated Fracture Healing: HBEGF Over<sup>Prx1</sup> mice exhibited significantly accelerated fracture healing, with near-complete bridging of fractures by 28 days post-fracture, compared to WT mice where the fracture gap remained visible.
  • Improved Bone Structure: HBEGF Over<sup>Prx1</sup> mice showed thicker trabecular and cortical bone structures, with increased bone volume fraction (BV/TV), trabecular number, and cortical thickness.
  • Enhanced Differentiation: Periosteal progenitors from HBEGF Over<sup>Prx1</sup> mice displayed enhanced chondrogenic, osteogenic, and angiogenic abilities in vitro.
  • EGFR Inhibition Reverses Effects: Treatment with gefitinib, an EGFR inhibitor, completely abolished the beneficial effects of HBEGF overexpression on fracture healing and bone formation.
  • Protective Against Osteoporosis: EGFR overactivation in Prx1+ cells protected against ovariectomy-induced bone loss, suggesting a role in maintaining bone health.
  • Angiogenesis Boost: HBEGF Over<sup>Prx1</sup> mice showed increased type H vessel formation in fracture callus, and conditioned medium from these cells enhanced HUVEC migration and tube formation.

Limitations and Future Work

  • Shortened Long Bone Phenotype: A notable observation was that HBEGF Over<sup>Prx1</sup> mice had shorter long bones. While the authors suggest this might be due to altered growth plate development, the precise mechanisms require further investigation.
  • Potential Carcinogenic Effects: The authors acknowledge that sustained EGFR activation is frequently observed in cancers. While they minimized this risk by targeting only stem/progenitor cells and observed no obvious organ changes in short-term studies, long-term pharmacological trials are necessary before clinical translation.
  • In Vitro vs. In Vivo Discrepancies: The authors note that their findings of increased bone markers with EGFR activation in vivo contradict some in vitro studies where exogenous EGFR ligands inhibited bone marker genes. They suggest dosage and experimental conditions might explain this, but further mechanistic studies are needed.
  • Future Directions: The authors propose exploring nanocarrier-based drug delivery systems for exogenous EGFR ligands to enhance their therapeutic efficacy and optimize conjugate structure, ligand choice, and dosage for bone repair. They also emphasize the need for further studies to address the potential carcinogenic concerns and fully elucidate the complex signaling networks involved.

Summary updated

Abstract

<b>Background:</b> Epidermal growth factor receptor (EGFR) signaling plays an important role in bone development. However, knowledge of its specific function in skeletal stem cells during bone healing remains scant. <b>Methods:</b> We used a lineage tracing approach and a stem/progenitor cell-specific EGFR overactivation mouse model which is generated by overexpressing heparin-binding EGF-like growth factor (HBEGF), an EGFR ligand, in Prx1-cre mice (<i>HBEGF Over<sup>Prx1</sup></i> ), to analyze the crucial roles of EGFR signaling in periosteal progenitor cells during fracture healing. <b>Results:</b> Compared with wild type, <i>HBEGF Over<sup>Prx1</sup></i> mice are found to have thicker trabecular and cortical bone structure and exhibit accelerated fracture healing. Single-cell RNA sequencing reveals that <i>HBEGF</i> is highly expressed in a periosteal progenitor cluster that constitutes a large portion of the callus cells and lays at the center of a developmental path that gives rise to chondrocytes and osteoblasts within the callus. <i>In vitro</i> experiments further demonstrate that periosteal progenitors isolated from <i>HBEGF Over<sup>Prx1</sup></i> mice display strong chondrogenic, osteogenic and angiogenic abilities, thus promoting fracture healing. Treating mice with gefitinib, an EGFR inhibitor, completely abolishes the promotional effects in <i>HBEGF Over<sup>Prx1</sup></i> mice. <b>Conclusion:</b> Our data reveal a cellular mechanism of EGFR signaling underlying fracture healing, and suggest that targeting EGFR may provide a potential therapeutic tool for delayed fracture healing or fracture non-union.
BibTeX
@inproceedings{hu2025overactivation,
  author = {Yuxiang Hu and Yangyang Chen and Xiang Peng and Haitao Li and Guo‐Si‐Lang Zuo and Hao Xu and Fashuai Wu and Yi Wang and Zengwu Shao and Yulong Wei},
  title = {{Overactivation of EGFR signaling in skeletal stem/progenitor cells promotes bone formation and repair}},
  booktitle = {Theranostics},
  year = {2025},
  doi = {10.7150/thno.115406},
}
Figure